A Phase I, Randomized, Observer Blind Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Zoster Vaccine (Adenovirus Vector) in Healthy Adults aged 50-65 years
In a Phase I randomized trial, an aerosol-administered ChAdOx1-VZV vaccine demonstrated superior CD8+ T cell induction and reduced reactogenicity compared to the licensed Shingrix® vaccine, though it elicited lower antibody responses.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Shingles is a painful reminder that some viruses never truly leave the body. After a person recovers from chickenpox, the virus that caused it hides quietly in the nerve clusters near the spine, waiting for years or even decades. When the immune system weakens, often due to aging, the virus can wake up and travel along a nerve to the skin, causing a blistering rash and intense pain. While antiviral medicines can treat the active infection, they cannot stop the virus from waking up in the first place. Vaccines exist to prevent this reactivation, but the most effective one currently available, while highly successful, often causes significant side effects like severe pain at the injection site, fever, and fatigue. These reactions can be so unpleasant that some people, particularly older adults, hesitate to get the second dose required for full protection. Scientists have long sought a vaccine that offers the same strong defense without the heavy toll on the body, hoping to find a way to train the immune system more gently but just as effectively.
A recent clinical trial conducted in Canada tested a new approach to this problem, exploring whether a different type of vaccine platform could change the rules of engagement against shingles. The researchers focused on a candidate vaccine built on a chimpanzee adenovirus, a harmless virus that acts as a delivery truck to carry instructions for a specific shingles protein into human cells. Unlike traditional vaccines that inject a piece of protein directly into muscle, this new candidate was designed to be inhaled as a fine mist, aiming to stimulate the immune system through the lungs. The study involved healthy adults between the ages of fifty and sixty-five, a group at increasing risk for shingles. The team compared this new inhaled vaccine, as well as the same vaccine given by a standard needle injection, against the current gold-standard vaccine and a saline placebo. The goal was not just to see if the new vaccine worked, but to see if it could do so with fewer side effects and by triggering a different, perhaps more powerful, type of immune response.
The results of the trial revealed a distinct trade-off between how the vaccine was delivered and what kind of protection it generated. When the researchers looked at the antibodies produced by the body, the traditional vaccine given by needle produced the highest levels, followed by the needle-administered new format, while the inhaled version produced the lowest levels. Antibodies are the proteins that float in the blood and can neutralize viruses, and in this specific study, the new vaccine did not generate as many of them as the established competitor. However, the story changed completely when the scientists examined the cellular immune response, which involves T-cells that hunt down and destroy infected cells. Here, the inhaled vaccine shone. It triggered a robust response from CD8+ T-cells, a specific type of white blood cell that acts as a specialized killer, capable of directly eliminating cells that have been infected by the virus. The standard vaccine, despite its high antibody numbers, failed to generate any noticeable activity from these killer cells. The inhaled vaccine also produced a strong response from CD4+ T-cells, which help coordinate the overall immune defense, matching the performance of the leading commercial vaccine.
Perhaps the most encouraging finding for patients was the difference in how the body reacted to the injections. The standard vaccine caused frequent and sometimes severe local reactions, with nearly every participant reporting pain or tenderness at the injection site, along with significant fatigue and headaches. In contrast, both the inhaled vaccine and the needle-administered new format showed favorable tolerability, with fewer and less intense symptoms than the standard shot. Participants who received the mist reported fewer side effects than those receiving the standard shot, and those that did occur were mild and short-lived. The vaccine given by needle in the new format also showed a better safety profile than the standard shot, with fewer people experiencing pain or systemic illness. This suggests that delivering the vaccine through the lungs or using the new needle formulation might bypass some of the intense local inflammation that occurs when the standard substance is forced into muscle tissue. The study confirmed that the new vaccine was safe, with no serious adverse events linked to the treatment, and that the virus used as the delivery vehicle did not persist in the blood after the initial dose.
The researchers concluded that this inhaled adenovirus-based vaccine offers a unique immunological profile that differs significantly from current options. While it did not match the antibody levels of the best existing vaccine, it succeeded in generating a powerful army of killer T-cells that the current vaccine lacks, all while causing far less discomfort to the recipient. This dual benefit of superior cellular immunity and high tolerability suggests a promising path forward, particularly for populations that might struggle with the side effects of current shots. The study did not prove that this vaccine would prevent shingles in the real world, as that requires further testing in larger groups and over longer periods, but it provided strong evidence that the strategy works. By showing that an inhaled vaccine can train the body's cellular defenses without the heavy burden of side effects, the trial opens a new door for how future vaccines might be designed to protect people from this persistent and painful virus.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.